Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen. Different doses of Grass MATA will be administered and immunological changes following this treatment will be assessed.
Grass MATA MPL has been developed to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting grass pollens. The grass pollen extract is modified with glutaraldehyde to produce the active ingredient, an allergoid. This modification reduces the reactivity of the extract with IgE antibody, thus reducing the risk of side effects. However, a simultaneous reduction in other important immunological properties, such as IgG and T cell reactivities, is not seen. MPL (Monophosphoryl Lipid A), a purified, detoxified glycolipid derived from the cell wall of Salmonella minnesota, is included in the product formulation as an adjuvant to increase the immunogenic effect of the product and to enhance the switch from an allergen-specific TH2 to a TH1-like T cell profile. The purpose of this study is to assess specific immunological changes (IgG, IgG1, IgG4 and IgE) in allergic subjects following 2 subcutaneous injections of different doses of study medication (Grass MATA or placebo) administered 3 weeks apart. The immunological changes will be used to assess the performance of the R7 IgG reactivity assay over a range of clinically efficacious doses.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
70
College Park Family Care Center Multi-Specialty Clinical Research
Overland Park, Kansas, United States
Northeast Medical Research Associates
North Dartmouth, Massachusetts, United States
Midwest Clinical research, LLC
St Louis, Missouri, United States
To assess specific immunological changes (IgG, IgG1, IgG4, IgE) in grass and rye allergic subjects following 2 subcutaneous injections of study medication (different doses of Grass MATA or placebo) administered 3 weeks apart.
adverse events
clinical laboratory evaluations
vital signs
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Allergy, Asthma, and Immunology Assoc. PC
Lincoln, Nebraska, United States
Asthma, Sinus, and Allergy Centers, LLC
Tinton Falls, New Jersey, United States
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States
Clinical Research Institute of Southern Oregon, PC
Medford, Oregon, United States
Allergy Associates Research Center
Portland, Oregon, United States
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania, United States
Asthma and Allergy Research Associates
Upland, Pennsylvania, United States
...and 1 more locations